Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein patched homolog 2 (PTCH2)
- Target
- PTCH2
- Molecular classification
- Receptor, Transmembrane protein, Transporter (Hedgehog receptor family)
01
Overview
Protein patched homolog 2 (PTCH2) is a **transmembrane cell-surface receptor** in the **Hedgehog signaling pathway**, structurally related to PTCH1, with which it shares a role as a receptor for all mammalian Hedgehog ligands, including Sonic Hedgehog (SHH), Desert Hedgehog (DHH), and Indian Hedgehog (IHH)[1][2]. PTCH2 regulates cell proliferation and differentiation during development and tissue maintenance, and it acts as a negative regulator of the Hedgehog pathway by inhibiting the activity of the Smoothened (SMO) protein in the absence of ligand. PTCH2 is particularly expressed in skin, testes, and certain embryonic tissues, and its dysfunction or loss can contribute to tumorigenesis, making it a relevant tumor suppressor in cancer such as basal cell carcinoma and germ cell tumors[1][2]. PTCH2's nonredundant roles with PTCH1, and its specific tissue expression pattern, underscore its unique biological and therapeutic significance in development and disease.
- Other names
- Patched 2PTC2SLC65B2UNQ560/PRO1121/PRO57079Patched homolog 2
02
Mechanism of action
Inhibition or modulation of Hedgehog pathway signaling, prevention of Smoothened (SMO) activation downstream of ligand (e.g., Sonic Hedgehog) binding[1][2]
03
Biological functions
Signal transductionControl of cellular growthEpidermal developmentMediator of Hedgehog signalingGerm cell development
04
Disease associations
Cancer (tumor suppressor in basal cell carcinoma, medulloblastoma, germ cell tumors)Inherited cancer syndromes (nevoid basal cell carcinoma syndrome)Developmental disorders (congenital macrostomia)
05
Safety considerations
On-target effects could potentially affect skin, hair, and reproductive organs due to roles in epidermal and germ cell development; redundancy with PTCH1 may limit clinical specificity; possible tumorigenic risk with pathway dysregulation[1][2][3]
06
Interacting drugs
None specifically reported or approved as of current knowledge; Hedgehog pathway inhibitors (such as vismodegib and sonidegib) *target components of this pathway, but their direct interaction with PTCH2 in clinical use is unclear*
07
Biomarkers
Expression of PTCH2 in selected tumors (e.g., germ cell tumors, basal cell carcinoma)Loss of heterozygosity or mutations in relevant syndromes
Beyond the preview
Go deeper on Protein patched homolog 2 (PTCH2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Protein patched homolog 2 (PTCH2).